Comparative in vitro activities of ciprofloxacin, clinafloxacin, gatifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae, and Enterobacter aerogenes clinical isolates with alterations in GyrA and ParC proteins - PubMed (original) (raw)

Comparative Study

Comparative in vitro activities of ciprofloxacin, clinafloxacin, gatifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae, and Enterobacter aerogenes clinical isolates with alterations in GyrA and ParC proteins

S Brisse et al. Antimicrob Agents Chemother. 1999 Aug.

Abstract

The in vitro activities of ciprofloxacin, clinafloxacin, gatifloxacin, levofloxacin, moxifloxacin, and trovafloxacin were tested against 72 ciprofloxacin-resistant and 28 ciprofloxacin-susceptible isolates of Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae, and Enterobacter aerogenes. Irrespective of the alterations in GyrA and ParC proteins, clinafloxacin exhibited greater activity than all other fluoroquinolones tested against K. pneumoniae and E. aerogenes.

PubMed Disclaimer

Similar articles

• Comparative activities of ciprofloxacin, clinafloxacin, gatifloxacin, gemifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against epidemiologically defined Acinetobacter baumannii strains.
  Heinemann B, Wisplinghoff H, Edmond M, Seifert H. Heinemann B, et al. Antimicrob Agents Chemother. 2000 Aug;44(8):2211-3. doi: 10.1128/AAC.44.8.2211-2213.2000. Antimicrob Agents Chemother. 2000. PMID: 10898706 Free PMC article.
• In-vitro antimicrobial activity of HSR-903, a new fluoroquinolone, against clinical isolates of Klebsiella pneumoniae and Enterobacter cloacae with fluoroquinolone resistance-associated amino acid alterations in GyrA and ParC.
  Deguchi T, Yasuda M, Kawamura T, Takahashi Y, Okezaki E, Nagata O, Kato H, Kawada Y. Deguchi T, et al. J Antimicrob Chemother. 1997 Dec;40(6):907-9. doi: 10.1093/jac/40.6.907. J Antimicrob Chemother. 1997. PMID: 9462448 No abstract available.
• Fluoroquinolones.
  [No authors listed] [No authors listed] 2020 Mar 10. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2020 Mar 10. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31643179 Free Books & Documents. Review.
• Enterobacter aerogenes and Enterobacter cloacae; versatile bacterial pathogens confronting antibiotic treatment.
  Davin-Regli A, Pagès JM. Davin-Regli A, et al. Front Microbiol. 2015 May 18;6:392. doi: 10.3389/fmicb.2015.00392. eCollection 2015. Front Microbiol. 2015. PMID: 26042091 Free PMC article. Review.

Cited by

• Molecular epidemiology of extended-spectrum beta-lactamase-producing, fluoroquinolone-resistant isolates of Klebsiella pneumoniae in Taiwan.
  Yu WL, Jones RN, Hollis RJ, Messer SA, Biedenbach DJ, Deshpande LM, Pfaller MA. Yu WL, et al. J Clin Microbiol. 2002 Dec;40(12):4666-9. doi: 10.1128/JCM.40.12.4666-4669.2002. J Clin Microbiol. 2002. PMID: 12454169 Free PMC article.
• Core/Whole Genome Multilocus Sequence Typing and Core Genome SNP-Based Typing of OXA-48-Producing Klebsiella pneumoniae Clinical Isolates From Spain.
  Miro E, Rossen JWA, Chlebowicz MA, Harmsen D, Brisse S, Passet V, Navarro F, Friedrich AW, García-Cobos S. Miro E, et al. Front Microbiol. 2020 Jan 31;10:2961. doi: 10.3389/fmicb.2019.02961. eCollection 2019. Front Microbiol. 2020. PMID: 32082262 Free PMC article.
• Modification of outer membrane protein profile and evidence suggesting an active drug pump in Enterobacter aerogenes clinical strains.
  Gayet S, Chollet R, Molle G, Pagès JM, Chevalier J. Gayet S, et al. Antimicrob Agents Chemother. 2003 May;47(5):1555-9. doi: 10.1128/AAC.47.5.1555-1559.2003. Antimicrob Agents Chemother. 2003. PMID: 12709321 Free PMC article.
• Klebsiella oxytoca Complex: Update on Taxonomy, Antimicrobial Resistance, and Virulence.
  Yang J, Long H, Hu Y, Feng Y, McNally A, Zong Z. Yang J, et al. Clin Microbiol Rev. 2022 Jan 19;35(1):e0000621. doi: 10.1128/CMR.00006-21. Epub 2021 Dec 1. Clin Microbiol Rev. 2022. PMID: 34851134 Free PMC article.
• Dissemination of ST274 Klebsiella pneumoniae epidemic clone in newborn and adult hospital settings harbouring SHV-2A or CTX-M-15 type extended spectrum β-lactamases-producing known plasmids.
  Damjanova I, Tóth A, Kenesei E, Köhalmi M, Szántai P, Füzi M, Pászti J. Damjanova I, et al. Eur J Microbiol Immunol (Bp). 2011 Sep;1(3):223-7. doi: 10.1556/EuJMI.1.2011.3.6. Epub 2011 Sep 9. Eur J Microbiol Immunol (Bp). 2011. PMID: 24516728 Free PMC article.

References

1. 1. Alarcon T, Pita J, Lopez-Brea M, Piddock L J. High-level quinolone resistance amongst clinical isolates of Escherichia coli and Klebsiella pneumoniae from Spain. J Antimicrob Chemother. 1993;32:605–609. - PubMed
2. 1. Bauernfeind A. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. J Antimicrob Chemother. 1997;40:639–651. - PubMed
3. 1. Bauernfeind A, Abele-Horn M, Emmerling P, Jungwirth R. Multiclonal emergence of ciprofloxacin-resistant clinical isolates of Escherichia coli and Klebsiella pneumoniae. J Antimicrob Chemother. 1994;34:1074–1076. - PubMed
4. 1. Belland R J, Morrison S G, Ison C, Huang W M. Neisseria gonorrhoeae acquires mutations in analogous regions of gyrA and parC in fluoroquinolone-resistant isolates. Mol Microbiol. 1994;14:371–380. - PubMed
5. 1. Deguchi T, Yasuda M, Asano M, Tada K, Iwata H, Komeda H, Ezaki T, Saito I, Kawada Y. DNA gyrase mutations in quinolone-resistant clinical isolates of Neisseria gonorrhoeae. Antimicrob Agents Chemother. 1995;39:561–563. - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Europe PubMed Central
  • PubMed Central